Adjuvants and myeloid-derived suppressor cells: Enemies or allies in therapeutic cancer vaccination

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 11, 2014, Pages 3251-3260

  Fernández, Audry ^a   Oliver, Liliana ^a   Alvarez, Rydell ^a   Fernández, Luis E ^a   Lee, Kelvin P ^b   Mesa, Circe ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Adjuvants; Cancer; Cytokines; Immunotherapy; MDSC; TLR ligands

Indexed keywords

ADENOVIRUS VECTOR; ALUMINUM POTASSIUM SULFATE; BEVACIZUMAB; CALCIFEDIOL; CANCER VACCINE; CPG OLIGODEOXYNUCLEOTIDE; CSF 470; DENDRITIC CELL VACCINE; FALIMAREV; FLUOROURACIL; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMIQUIMOD; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 7; LYMPHOMA VACCINE; MONTANIDE ISA 51; NELIPEPIMUT S; PEPTIDE VACCINE; POLYINOSINIC POLYCYTIDYLIC ACID; QS 21; RACOTUMOMAB; RESIQUIMOD; RETINOIC ACID; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VESIGENURTUCEL L; CYTOKINE; SIGNAL PEPTIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOPTIVE TRANSFER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER GENE THERAPY; CANCER IMMUNIZATION; COLON CANCER; DRUG EFFECT; DRUG MEGADOSE; ESOPHAGUS CANCER; GLIOBLASTOMA; GLIOMA; HUMAN; IMMUNE DEFICIENCY; KIDNEY CARCINOMA; LUNG CANCER; MEDIASTINUM CANCER; MELANOMA; METASTATIC MELANOMA; MYELOID DERIVED SUPPRESSOR CELL; MYELOMA; NON SMALL CELL LUNG CANCER; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PLEURA CANCER; PROSTATE CANCER; RADIOFREQUENCY ABLATION; SOLID TUMOR; SUPPRESSOR CELL; T LYMPHOCYTE ACTIVATION; UTERINE CERVIX CANCER; BONE MARROW CELL; CELL DIFFERENTIATION; CYTOLOGY; DENDRITIC CELL; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MACROPHAGE; NEOPLASMS; T LYMPHOCYTE; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; CANCER VACCINES; CELL DIFFERENTIATION; CYTOKINES; DENDRITIC CELLS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOCYTE ACTIVATION; MACROPHAGES; MYELOID CELLS; NEOPLASMS; T-LYMPHOCYTES; VACCINATION;

EID: 84921762780     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.29847     Document Type: Article

References (110)

1. Stagg J, Johnstone RW, Smyth MJ. From cancer immunosurveillance to cancer immunotherapy. Immunol Rev 2007; 220:82-101; PMID:17979841; http://dx.doi.org/10.1111/j.1600-065X.2007.00566.x
2. Lizee G, Overwijk WW, Radvanyi L, Gao J, Sharma P, Hwu P. Harnessing the power of the immune system to target cancer. Ann Rev Med 2013; 64:71-90; PMID:23092383; http://dx.doi.org/10.1146/annurev-med-112311-083918
3. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012; 21:309-22; PMID:22439926; http://dx.doi.org/10.1016/j.ccr.2012.02.022
4. Palena C, Schlom J. Vaccines against human carcinomas: strategies to improve antitumor immune responses. J Biomed Biotechnol 2010; 2010:380697; PMID:20300434; http://dx.doi.org/10.1155/2010/380697
5. Talmadge JE, Gabrilovich DI. History of myeloid-derived suppressor cells. Nat Rev Cancer 2013; 13:739-52; PMID:24060865; http://dx.doi.org/10.1038/nrc3581
6. Diaz-Montero CM, Salem ML, Nishimura MI, Gar-rett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 2009; 58:49-59; PMID:18446337; http://dx.doi.org/10.1007/s00262-008-0523-4
7. Solito S, Falisi E, Diaz-Montero CM, Doni A, Pinton L, Rosato A, Francescato S, Basso G, Zanovello P, Onicescu G, et al. A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood 2011; 118:2254-65; PMID:21734236; http://dx.doi. org/10.1182/blood-2010-12-325753
8. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12:253-68; PMID:22437938; http://dx.doi.org/10.1038/nri3175
9. Schlom J. Therapeutic cancer vaccines: current status and moving forward. J Nat Cancer Inst 2012; 104:599-613; PMID:22395641; http://dx.doi.org/10.1093/jnci/djs033
10. Awate S, Babiuk LA, Mutwiri G. Mechanisms of action of adjuvants. Front Immunol 2013; 4:114; PMID:23720661; http://dx.doi.org/10.3389/fimmu.2013.00114
11. Finn OJ. Cancer vaccines: between the idea and the reality. Nat Rev Immunol 2003; 3:630-41; PMID:12974478; http://dx.doi.org/10.1038/nri1150
12. Vatsan RS, Bross PF, Liu K, Theoret M, De Claro AR, Lu J, Helms W, Niland B, Husain SR, Puri RK. Regulation of immunotherapeutic products for cancer and FDA's role in product development and clinical evaluation. J Immunother Cancer 2013; 1:5; PMID:24764535; http://dx.doi.org/10.1186/2051-1426-1-5
13. Serafini P, Borrello I, Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 2006; 16:53-65; PMID:16168663; http://dx.doi.org/10.1016/j.semcancer.2005.07.005
14. Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 2007; 117:1155-66; PMID:17476345; http://dx.doi.org/10.1172/JCI31422
15. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 2008; 181:5791-802; PMID:18832739; http://dx.doi.org/10.4049/jimmunol.181.8.5791
16. Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, Beschin A, De Baetselier P, Van Ginderachter JA. Identification of discrete tumor-induced myeloid-derived suppressor cell sub-populations with distinct T cell-suppressive activity. Blood 2008; 111:4233-44; PMID:18272812; http://dx.doi.org/10.1182/blood-2007-07-099226
17. Dolcetti L, Peranzoni E, Ugel S, Marigo I, Fernandez Gomez A, Mesa C, Geilich M, Winkels G, Traggiai E, Casati A, et al. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol 2010; 40:22-35; PMID:19941314; http://dx.doi.org/10.1002/eji.200939903
18. Liu C, Yu S, Kappes J, Wang J, Grizzle WE, Zinn KR, Zhang HG. Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host. Blood 2007; 109:4336-42; PMID:17244679; http://dx.doi.org/10.1182/blood-2006-09-046201
19. Serafini P. Myeloid derived suppressor cells in physiological and pathological conditions: the good, the bad, and the ugly. Immunol Res 2013; 57:172-84; PMID:24203443; http://dx.doi.org/10.1007/s12026-013-8455-2
20. Montero AJ, Diaz-Montero CM, Kyriakopoulos CE, Bronte V, Mandruzzato S. Myeloid-derived suppressor cells in cancer patients: a clinical perspective. J Immunother 2012; 35:107-15; PMID:22306898; http://dx.doi.org/10.1097/CJI.0b013e318242169f
21. Serafini P, Meckel K, Kelso M, Noonan K, Califano J, Koch W, Dolcetti L, Bronte V, Borrello I. Phosphodi-esterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 2006; 203:2691-702; PMID:17101732; http://dx.doi.org/10.1084/jem.20061104
22. Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, Golshayan A, Rayman PA, Wood L, Garcia J, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009; 15:2148-57; PMID:19276286; http://dx.doi.org/10.1158/1078-0432.CCR-08-1332
23. Gabitass RF, Annels NE, Crawshaw J. American society clinical oncology annual meeting, Chicago. J Clin Oncol 2011; 29: (suppl abstr 2588).
24. Martino A, Badell E, Abadie V, Balloy V, Chignard M, Mistou MY, Combadiere B, Combadiere C, Winter N. Mycobacterium bovis bacillus Calmette-Guerin vaccination mobilizes innate myeloid-derived suppressor cells restraining in vivo T cell priming via IL-1Rdependent nitric oxide production. J Immunol 2010; 184:2038-47; PMID:20083674; http://dx.doi.org/10.4049/jimmunol.0903348
25. Condamine T, Gabrilovich DI. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol 2011; 32:19-25; PMID:21067974; http://dx.doi.org/10.1016/j.it.2010.10.002
26. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010; 11:373-84; PMID:20404851; http://dx.doi.org/10.1038/ni.1863
27. Vacchelli E, Eggermont A, Sautes-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: toll-like receptor agonists for cancer therapy. Oncoimmunology 2013; 2:e25238; PMID:24083080; http:// dx.doi.org/10.4161/onci.25238
28. Krieg AM. CpG motifs: the active ingredient in bacterial extracts? Nat Med 2003; 9:831-5; PMID:12835699; http://dx.doi.org/10.1038/nm0703-831
29. Krug A, Rothenfusser S, Selinger S, Bock C, Kerkmann M, Battiany J, Sarris A, Giese T, Speiser D, Endres S, et al. CpG-A oligonucleotides induce a monocyte-derived dendritic cell-like phenotype that preferentially activates CD8 T cells. J Immunol 2003; 170:3468-77; PMID:12646607; http://dx.doi.org/10.4049/jimmunol.170.7.3468
30. Cheng YS, Xu F. Anticancer function of polyinosinicpolycytidylic acid. Cancer Biol Ther 2010; 10:1219-23; PMID:20930504; http://dx.doi.org/10.4161/cbt.10.12.13450
31. Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science 2010; 327:291-5; PMID:20075244; http://dx.doi.org/10.1126/science.1183021
32. Pulendran B, Tang H, Manicassamy S. Programming dendritic cells to induce T(H)2 and tolerogenic responses. Nat Immunol 2010; 11:647-55; PMID:20644570; http://dx.doi.org/10.1038/ni.1894
33. Cauley LS, Miller EE, Yen M, Swain SL. Superantigen-induced CD4 T cell tolerance mediated by myeloid cells and IFN-gamma. J Immunol 2000; 165:6056-66; PMID:11086037; http://dx.doi.org/10.4049/jimmunol.165.11.6056
34. Makarenkova VP, Bansal V, Matta BM, Perez LA, Ochoa JB. CD11bCGr-1 Cmyeloid suppressor cells cause T cell dysfunction after traumatic stress. J Immunol 2006; 176:2085-94; PMID:16455964; http://dx.doi.org/10.4049/jimmunol.176.4.2085
35. Murphey ED, Lin CY, McGuire RW, Toliver-Kinsky T, Herndon DN, Sherwood ER. Diminished bacterial clearance is associated with decreased IL-12 and inter-feron-gamma production but a sustained proinflammatory response in a murine model of postseptic immunosuppression. Shock 2004; 21:415-25; PMID:15087817; http://dx.doi.org/10.1097/00024382-200405000-00004
36. Scumpia PO, Kelly-Scumpia KM, Delano MJ, Weinstein JS, Cuenca AG, Al-Quran S, Bovio I, Akira S, Kumagai Y, Moldawer LL. Cutting edge: bacterial infection induces hematopoietic stem and progenitor cell expansion in the absence of TLR signaling. J Immunol 2010; 184:2247-51; PMID:20130216; http://dx.doi.org/10.4049/jimmunol.0903652
37. Morecki S, Gelfand Y, Yacovlev E, Eizik O, Shabat Y, Slavin S. CpG-induced myeloid CD11bCGr-1C cells efficiently suppress T cell-mediated immunoreactivity and graft-versus-host disease in a murine model of allogeneic cell therapy. Biol Blood Marrow Transplant 2008; 14:973-84; PMID:18721760; http://dx.doi.org/10.1016/j.bbmt.2008.06.018
38. Wang Z, Jiang J, Li Z, Zhang J, Wang H, Qin Z. A myeloid cell population induced by Freund adjuvant suppresses T-cell-mediated antitumor immunity. J Immunother 2010; 33:167-77; PMID:20145547; http://dx.doi.org/10.1097/CJI.0b013e3181bed2ba
39. De Wilde V, Van Rompaey N, Hill M, Lebrun JF, Lemaitre P, Lhomme F, Kubjak C, Vokaer B, Oldenhove G, Charbonnier LM, et al. Endotoxin-induced myeloid-derived suppressor cells inhibit alloimmune responses via heme oxygenase-1. Am J Transplant 2009; 9:2034-47; PMID:19681826; http://dx.doi. org/10.1111/j.1600-6143.2009.02757.x
40. Fernandez A, Mesa C, Marigo I, Dolcetti L, Clavell M, Oliver L, Fernandez LE, Bronte V. Inhibition of tumor-induced myeloid-derived suppressor cell function by a nanoparticulated adjuvant. J Immunol 2011; 186:264-74; PMID:21135171; http://dx.doi. org/10.4049/jimmunol.1001465
41. Eisenbarth SC, Colegio OR, O'Connor W, Sutterwala FS, Flavell RA. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008; 453:1122-6; PMID:18496530; http://dx.doi.org/10.1038/nature06939
42. Li H, Nookala S, Re F. Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1beta and IL-18 release. J Immunol 2007; 178:5271-6; PMID:17404311; http://dx.doi.org/10.4049/jimmunol.178.8.5271
43. Brys L, Beschin A, Raes G, Ghassabeh GH, Noel W, Brandt J, Brombacher F, De Baetselier P. Reactive oxygen species and 1215-lipoxygenase contribute to the antiproliferative capacity of alternatively activated myeloid cells elicited during helminth infection. J Immunol 2005; 174:6095-104; PMID:15879104; http://dx.doi.org/10.4049/jimmunol.174.10.6095
44. Van Ginderachter JA, Beschin A, De Baetselier P, Raes G. Myeloid-derived suppressor cells in parasitic infections. Eur J Immunol 2010; 40:2976-85; PMID:21061431; http://dx.doi.org/10.1002/eji.201040911
45. Bronte V, Chappell DB, Apolloni E, Cabrelle A, Wang M, Hwu P, Restifo NP. Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8C T cell responses by dysregulating antigen-presenting cell maturation. J Immunol 1999; 162:5728-37; PMID:10229805
46. Gallina G, Dolcetti L, Serafini P, De Santo C, Marigo I, Colombo MP, Basso G, Brombacher F, Borrello I, Zanovello P, et al. Tumors induce a subset of inflammatory monocytes with immuno-suppressive activity on CD8 C T cells. J Clin Invest 2006; 116:2777-90; PMID:17016559; http://dx.doi.org/10.1172/JCI28828
47. Kusmartsev S, Gabrilovich DI. STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J Immunol 2005; 174:4880-91; PMID:15814715; http://dx.doi.org/10.4049/jimmunol.174.8.4880
48. Bronte V, Serafini P, Mazzoni A, Segal DM, Zanovello P. L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol 2003; 24:302-6; PMID:12810105; http://dx.doi.org/10.1016/S1471-4906(03)00132-7
49. Fernández A, Oliver L, Alvarez R, Hernández A, Raymond J, Fernández L, Mesa C. Very small size proteoliposomes abrogate crosspresentation of tumor antigens by myeloid-derived suppressor cells and induce their differentiation to dendritic cells. J Immunother Cancer 2014; 2:5; PMID:24829762; http://dx.doi.org/10.1186/2051-1426-2-5
50. Shirota Y, Shirota H, Klinman DM. Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells. J Immunol 2012; 188:1592-9; PMID:22231700; http://dx.doi.org/10.4049/jimmunol.1101304
51. Volpi C, Fallarino F, Pallotta MT, Bianchi R, Vacca C, Belladonna ML, Orabona C, De Luca A, Boon L, Romani L, et al. High doses of CpG oligodeoxynucleotides stimulate a tolerogenic TLR9-TRIF pathway. Nat Commun 2013; 4:1852; PMID:23673637; http://dx.doi.org/10.1038/ncomms2874
52. Zoglmeier C, Bauer H, Norenberg D, Wedekind G, Bittner P, Sandholzer N, Rapp M, Anz D, Endres S, Bourquin C. CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice. Clin Cancer Res 2011; 17:1765-75; PMID:21233400; http://dx.doi.org/10.1158/1078-0432.CCR-10-2672
53. Lee M, Park CS, Lee YR, Im SA, Song S, Lee CK. Resiquimod, a TLR78 agonist, promotes differentiation of myeloid-derived suppressor cells into macrophages and dendritic cells. Arch Pharm Res 2014; 37:1234-40; PMID:24748512; http://dx.doi.org/10.1007/s12272-014-0379-4
54. Greifenberg V, Ribechini E, Rossner S, Lutz MB. Myeloid-derived suppressor cell activation by combined LPS and IFN-gamma treatment impairs DC development. Eur J Immunol 2009; 39:2865-76; PMID:19637228; http://dx.doi.org/10.1002/eji.200939486
55. Inaba K, Steinman RM, Pack MW, Aya H, Inaba M, Sudo T, Wolpe S, Schuler G. Identification of proliferating dendritic cell precursors in mouse blood. J Exp Med 1992; 175:1157-67; PMID:1569392; http://dx.doi.org/10.1084/jem.175.5.1157
56. van de Laar L, Coffer PJ, Woltman AM. Regulation of dendritic cell development by GM-CSF: molecular control and implications for immune homeostasis and therapy. Blood 2012; 119:3383-93; PMID:22323450; http://dx.doi.org/10.1182/blood-2011-11-370130
57. Dranoff G. GM-CSF-secreting melanoma vaccines. Oncogene 2003; 22:3188-92; PMID:12789295; http://dx.doi.org/10.1038/sj.onc.1206459
58. Serafini P, Carbley R, Noonan KA, Tan G, Bronte V, Borrello I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 2004; 64:6337-43; PMID:15342423; http://dx.doi.org/10.1158/0008-5472.CAN-04-0757
59. Bayne LJ, Beatty GL, Jhala N, Clark CE, Rhim AD, Stanger BZ, Vonderheide RH. Tumor-derived granu-locyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 2012; 21:822-35; PMID:22698406; http://dx.doi.org/10.1016/j.ccr.2012.04.025
60. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162-74; PMID:19197294; http:// dx.doi.org/10.1038/nri2506
61. Parmiani G, Castelli C, Pilla L, Santinami M, Colombo MP, Rivoltini L. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol 2007; 18:226-32; PMID:17116643; http://dx.doi.org/10.1093/annonc/mdl158
62. Cheever MA. Twelve immunotherapy drugs that could cure cancers. Immunol Rev 2008; 222:357-68; PMID:18364014; http://dx.doi.org/10.1111/j.1600-065X.2008.00604.x
63. Xu M, Mizoguchi I, Morishima N, Chiba Y, Mizuguchi J, Yoshimoto T. Regulation of antitumor immune responses by the IL-12 family cytokines, IL-12, IL-23, and IL-27. Clin Dev Immunol 2010; 2010; 832454; PMID:20885915; http://dx.doi.org/10.1155/2010/832454
64. Smyth MJ, Taniguchi M, Street SE. The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent. J Immunol 2000; 165:2665-70; PMID:10946296; http://dx.doi.org/10.4049/jimmunol.165.5.2665
65. Robertson MJ, Ritz J. Interleukin 12: basic biology and potential applications in cancer treatment. Oncologist 1996; 1:88-97; PMID:10387973
66. Hamza T, Barnett JB, Li B. Interleukin 12 a key immunoregulatory cytokine in infection applications. Int J Mol Sci 2010; 11:789-806; PMID:20479986; http://dx.doi.org/10.3390/ijms11030789
67. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995; 13:251-76; PMID:7612223; http://dx.doi.org/10.1146/annurev.iy.13.040195.001343
68. Kerkar SP, Goldszmid RS, Muranski P, Chinnasamy D, Yu Z, Reger RN, Leonardi AJ, Morgan RA, Wang E, Marincola FM, et al. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest 2011; 121:4746-57; PMID:22056381; http://dx.doi.org/10.1172/JCI58814
69. Steding E, Wu ST, Zhang Y, Jeng MH, Elzey BD, Kao C. The role of interleukin-12 on modulating myeloid-derived suppressor cells, increasing overall survival and reducing metastasis. Immunology 2011; 133:221-38; PMID:21453419; http://dx.doi.org/10.1111/j.1365-2567.2011.03429.x
70. Thaci B, Ahmed AU, Ulasov IV, Wainwright DA, Nigam P, Auffinger B, Tobias AL, Han Y, Zhang L, Moon KS, et al. Depletion of myeloid-derived suppressor cells during interleukin-12 immunogene therapy does not confer a survival advantage in experimental malignant glioma. Cancer Gene Ther 2014; 21:38-44; PMID:24434573; http://dx.doi.org/10.1038/cgt.2013.81
71. Kerkar SP, Leonardi AJ, van Panhuys N, Zhang L, Yu Z, Crompton JG, Pan JH, Palmer DC, Morgan RA, Rosenberg SA, et al. Collapse of the tumor stroma is triggered by IL-12 induction of Fas. Mol Ther: J Am Soc Gene Ther 2013; 21:1369-77; PMID:23568260; http://dx.doi.org/10.1038/mt.2013.58
72. Petrella T, Quirt I, Verma S, Haynes AE, Charette M, Bak K, Melanoma disease site group of cancer care ontario's program in evidence-based C. Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review. Cancer Treat Rev 2007; 33:484-96; PMID:17562357; http://dx.doi.org/10.1016/j.ctrv.2007.04.003
73. McDermott DF, Atkins MB. Immunotherapy of metastatic renal cell carcinoma. Cancer J 2008; 14:320-4; PMID:18836337; http://dx.doi.org/10.1097/PPO.0b013e31818675c4
74. Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 2006; 6:595-601; PMID:16868550; http://dx.doi.org/10.1038/nri1901
75. Sato N, Patel HJ, Waldmann TA, Tagaya Y. The IL-15IL-15Ralpha on cell surfaces enables sustained IL-15 activity and contributes to the long survival of CD8 memory T cells. Proc Natl Acad Sci U S A 2007; 104:588-93; PMID:17202253; http://dx.doi. org/10.1073/pnas.0610115104
76. Melchionda F, Fry TJ, Milliron MJ, McKirdy MA, Tagaya Y, Mackall CL. Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8C memory cell pool. J Clin Invest 2005;115:1177-87; PMID:15841203; http://dx.doi.org/10.1172/JCI200523134
77. Overwijk WW, Schluns KS. Functions of gammaC cytokines in immune homeostasis: current and potential clinical applications. Clin Immunol 2009;132:153-65; PMID:19428306; http://dx.doi.org/10.1016/j.clim.2009.03.512
78. Smith FO, Downey SG, Klapper JA, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Restifo NP, Levy CL, et al. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res 2008; 14:5610-8; PMID:18765555; http://dx.doi.org/10.1158/1078-0432.CCR-08-0116
79. Heemskerk B, Liu K, Dudley ME, Johnson LA, Kaiser A, Downey S, Zheng Z, Shelton TE, Matsuda K, Robbins PF, et al. Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2. Hum Gene Ther 2008; 19:496-510; PMID:18444786; http://dx.doi.org/10.1089/hum.2007.0171
80. Kovanen PE, Leonard WJ. Cytokines and immunodeficiency diseases: critical roles of the gamma(c)-dependent cytokines interleukins 2, 4, 7, 9, 15, and 21, and their signaling pathways. Immunol Rev 2004; 202:67-83; PMID:15546386; http://dx.doi.org/10.1111/j.0105-2896.2004.00203.x
81. Liao W, Lin JX, Wang L, Li P, Leonard WJ. Modulation of cytokine receptors by IL-2 broadly regulates differentiation into helper T cell lineages. Nat Immunol 2011; 12:551-9; PMID:21516110; http://dx.doi.org/10.1038/ni.2030
82. Cesana GC, DeRaffele G, Cohen S, Moroziewicz D, Mitcham J, Stoutenburg J, Cheung K, Hesdorffer C, Kim-Schulze S, Kaufman HL. Characterization of CD4CCD25C regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 2006; 24:1169-77; PMID:16505437; http://dx.doi.org/10.1200/JCO.2005.03.6830
83. Habibi M, Kmieciak M, Graham L, Morales JK, Bear HD, Manjili MH. Radiofrequency thermal ablation of breast tumors combined with intralesional administration of IL-7 and IL-15 augments anti-tumor immune responses and inhibits tumor development and metastasis. Breast Cancer Res Treat 2009;114:423-31; PMID:18425677; http://dx.doi.org/10.1007/s10549-008-0024-3
84. Rodriguez PC, Ernstoff MS, Hernandez C, Atkins M, Zabaleta J, Sierra R, Ochoa AC. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 2009; 69:1553-60; PMID:19201693; http://dx.doi.org/10.1158/0008-5472.CAN-08-1921
85. Huang B, Pan PY, Li Q, Sato AI, Levy DE, Bromberg J, Divino CM, Chen SH. Gr-1CCD115C immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 2006; 66:1123-31; PMID:16424049; http://dx.doi.org/10.1158/0008-5472.CAN-05-1299
86. Zhang Y, Liu Q, Zhang M, Yu Y, Liu X, Cao X. Fas signal promotes lung cancer growth by recruiting myeloid-derived suppressor cells via cancer cellderived PGE2. J Immunol 2009; 182:3801-8; PMID:19265159; http://dx.doi.org/10.4049/jimmunol.0801548
87. Fujimura T, Ring S, Umansky V, Mahnke K, Enk AH. Regulatory T cells stimulate B7-H1 expression in myeloid-derived suppressor cells in ret melanomas. J Invest Dermatol 2012; 132:1239-46; PMID:22189788; http://dx.doi.org/10.1038/jid.2011.416
88. Yang R, Cai Z, Zhang Y, Yutzy WHt, Roby KF, Roden RB. CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1CCD11bC myeloid cells. Cancer Res 2006; 66:6807-15; PMID:16818658; http://dx.doi.org/10.1158/0008-5472.CAN-05-3755
89. Weiss JM, Back TC, Scarzello AJ, Subleski JJ, Hall VL, Stauffer JK, Chen X, Micic D, Alderson K, Murphy WJ, et al. Successful immunotherapy with IL-2anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment. Proc Natl Acad Sci U S A 2009; 106:19455-60; PMID:19892741; http://dx.doi.org/10.1073/pnas.0909474106
90. Bryant PW, Lennon-Dumenil AM, Fiebiger E, Lagaudriere-Gesbert C, Ploegh HL. Proteolysis and antigen presentation by MHC class II molecules. Adv Immunol 2002; 80:71-114; PMID:12078484; http://dx.doi.org/10.1016/S0065-2776(02)80013-X
91. Ramachandra L, Simmons D, Harding CV. MHC molecules and microbial antigen processing in phagosomes. Curr Opin Immunol 2009; 21:98-104; PMID:19217269; http://dx.doi.org/10.1016/j.coi.2009.01.001
92. Purcell AW, Elliott T. Molecular machinations of the MHC-I peptide loading complex. Curr Opin Immunol 2008; 20:75-81; PMID:18243674; http://dx.doi.org/10.1016/j.coi.2007.12.005
93. Rock KL, York IA, Goldberg AL. Post-proteasomal antigen processing for major histocompatibility complex class I presentation. Nat Immunol 2004; 5:670-7; PMID:15224092; http://dx.doi.org/10.1038/ni1089
94. Joffre OP, Segura E, Savina A, Amigorena S. Crosspresentation by dendritic cells. Nat Rev Immunol 2012; 12:557-69; PMID:22790179; http://dx.doi.org/10.1038/nri3254
95. Gregory AE, Titball R, Williamson D. Vaccine delivery using nanoparticles. Front Cell Infect Microbiol 2013; 3:13; PMID:23532930
96. Gupta RK, Singh M, O'Hagan DT. Poly(lactide-coglycolide) microparticles for the development of single-dose controlled-release vaccines. Adv Drug Deliv Rev 1998; 32:225-46; PMID:10837646; http://dx. doi.org/10.1016/S0169-409X(98)00008-8
97. Lo-Man R, Rueda P, Sedlik C, Deriaud E, Casal I, Leclerc C. A recombinant virus-like particle system derived from parvovirus as an efficient antigen carrier to elicit a polarized Th1 immune response without adjuvant. Eur J Immunol 1998; 28:1401-7; PMID:9565380; http://dx.doi.org/10.1002/(SICI)1521-4141(199804)28:04%3c1401::AID-IMMU1401%3e3.0.CO;2-M
98. Quinn KM, Yamamoto A, Costa A, Darrah PA, Lindsay RW, Hegde ST, Johnson TR, Flynn BJ, Lore K, Seder RA. Coadministration of polyinosinic:polycytidylic acid and immunostimulatory complexes modifies antigen processing in dendritic cell subsets and enhances HIV gag-specific T cell immunity. J Immunol 2013; 191:5085-96; PMID:24089189; http://dx. doi.org/10.4049/jimmunol.1301730
99. Takahashi H, Takeshita T, Morein B, Putney S, Germain RN, Berzofsky JA. Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs. Nature 1990; 344:873-5; PMID:2184369; http://dx.doi.org/10.1038/344873a0
100. Srivastava P. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol 2002; 20:395-425; PMID:11861608; http://dx.doi.org/10.1146/annurev.immunol.20.100301.064801
101. Mesa C, de Leon J, Fernandez LE. Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for generation of CTL responses to peptide and protein antigens. Vaccine 2006; 24:2692-9; PMID:16316710; http://dx.doi.org/10.1016/j.vaccine.2005.08.111
102. Ugel S, Peranzoni E, Desantis G, Chioda M, Walter S, Weinschenk T, Ochando JC, Cabrelle A, Mandruzzato S, Bronte V. Immune tolerance to tumor antigens occurs in a specialized environment of the spleen. Cell Rep 2012; 2:628-39; PMID:22959433; http://dx.doi. org/10.1016/j.celrep.2012.08.006
103. Siskind GW, Benacerraf B. Cell selection by antigen in the immune response. Adv Immunol 1969; 10:1-50; PMID:4900673; http://dx.doi.org/10.1016/S0065-2776(08)60414-9
104. Didierlaurent AM, Morel S, Lockman L, Giannini SL, Bisteau M, Carlsen H, Kielland A, Vosters O, Vanderheyde N, Schiavetti F, et al. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 2009; 183:6186-97; PMID:19864596; http://dx.doi. org/10.4049/jimmunol.0901474
105. Neninger E, Diaz RM, de la Torre A, Rives R, Diaz A, Saurez G, Gabri MR, Alonso DF, Wilkinson B, Alfonso AM, et al. Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: report of a phase I trial. Cancer Biol Ther 2007; 6:145-50; PMID:17218777; http://dx.doi.org/10.4161/cbt.6.2.3574
106. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10:909-15; PMID:15340416; http://dx.doi.org/10.1038/nm1100
107. Hailemichael Y, Dai Z, Jaffarzad N, Ye Y, Medina MA, Huang XF, Dorta-Estremera SM, Greeley NR, Nitti G, Peng W, et al. Persistent antigen at vaccination sites induces tumor-specific CD8(+) T cell sequestration, dysfunction and deletion. Nat Med 2013; 19:465-72; PMID:23455713; http://dx.doi. org/10.1038/nm.3105
108. Rosenberg SA, Sherry RM, Morton KE, Scharfman WJ, Yang JC, Topalian SL, Royal RE, Kammula U, Restifo NP, Hughes MS, et al. Tumor progression can occur despite the induction of very high levels of selftumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol 2005; 175:6169-76; PMID:16237114; http://dx.doi.org/10.4049/jimmunol.175.9.6169
109. Hamid O, Solomon JC, Scotland R, Garcia M, Sian S, Ye W, Groshen SL, Weber JS. Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: correlation with time to relapse in patients with resected high-risk disease. Clin Cancer Res 2007; 13:215-22; PMID:17200357; http://dx.doi.org/10.1158/1078-0432.CCR-06-1450
110. MacLeod MK, McKee AS, David A, Wang J, Mason R, Kappler JW, Marrack P. Vaccine adjuvants aluminum and monophosphoryl lipid A provide distinct signals to generate protective cytotoxic memory CD8 T cells. Proc Natl Acad Sci U S A 2011; 108:7914-9; PMID:21518876; http://dx.doi.org/10.1073/pnas.1104588108